| Abstract | We report the case of a woman with HER2-positive metastatic breast cancer who achieved prolonged complete remission of multiple liver metastases after treatment with weekly trastuzumab plus paclitaxel but relapsed in the brain soon after stopping trastuzumab maintenance therapy which had been prosecuted for almost three years. In the absence of randomized trials, the optimal duration of trastuzumab administration after achieving complete remission of metastatic breast cancer remains questionable. |
| Authors | Manuela Beda, Umberto Basso, Cristina Ghiotto, Silvio Monfardini
(Affiliation: Department of Medical Oncology, Istituto Oncologico Veneto-IOV, Padua, Italy. m.beda at libero.it)
|
| Journal | Tumori
(Tumori)
2007 Sep-Oct
Vol. 93
Issue 5
Pg. 491-2
ISSN: 0300-8916 Italy |
| PMID | 18038883
(Publication Type: Case Reports, Journal Article)
|
| Chemical References |
- Antibodies, Monoclonal
- Antineoplastic Agents
- trastuzumab
- Receptor, erbB-2
|
| Topics |
- Adult
- Antibodies, Monoclonal
(therapeutic use)
- Antineoplastic Agents
(therapeutic use)
- Brain Neoplasms
(metabolism, prevention & control, secondary)
- Breast Neoplasms
(drug therapy, metabolism, pathology)
- Female
- Humans
- Liver Neoplasms
(drug therapy, metabolism, secondary)
- Receptor, erbB-2
(metabolism)
- Remission Induction
- Time Factors
|
